Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case

Shelly S. Lo, Georgios I. Papachristou, Sydney D. Finkelstein, William P. Conroy, Wolfgang H. Schraut, Ramesh K. Ramanathan

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.

Original languageEnglish (US)
Pages (from-to)1316-1319
Number of pages4
JournalDiseases of the colon and rectum
Issue number6
StatePublished - Jun 2005


  • Gastrointestinal stromal tumor
  • Imatinib
  • Microdissection genotyping
  • Rectal tumor

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case'. Together they form a unique fingerprint.

Cite this